TY - JOUR
T1 - Debate on long-acting β agonists for asthma
T2 - they think it's all over
AU - Lipworth, Brian
AU - Jabbal, Sunny
N1 - BL reports grants and personal fees from Teva, Boehringer Ingelheim, Meda, and Chiesi Pharma; personal fees from Dr Reddy's, Sandoz, and Lupin; grants from AstraZeneca, Janssen, Roche, and Sanofi; and other support from Napp, outside of the submitted work. SJ reports personal fees and non-financial support from Chiesi Pharma, non-financial support from Pfizer and Napp, and other support from Napp, outside of the submitted work.
PY - 2017/3
Y1 - 2017/3
N2 - At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?
AB - At last, we can apparently relax in the secure knowledge that long-acting β agonists (LABA) are safe to use in persistent asthma when given in combination with inhaled corticosteroid (ICS), on the basis of the US Food and Drug Administration-mandated studies1,2 with either fluticasone–salmeterol or budesonide–formoterol. These combinations showed no increase in serious asthma-related events and both reduced exacerbations compared with ICS alone. Do these results mean we can now prescribe ICS–LABA combination inhalers with impunity at step 3 and above of asthma guidelines?
KW - Letter
U2 - 10.1016/S2213-2600(17)30053-X
DO - 10.1016/S2213-2600(17)30053-X
M3 - Letter
C2 - 28266330
SN - 2213-2600
VL - 5
SP - e14-e15
JO - The Lancet Respiratory Medicine
JF - The Lancet Respiratory Medicine
IS - 3
ER -